Resverlogix Corp. has restructured its clinical CVD program, which will now be formally directed by Dr. Jan Johansson. The Company would like to thank Dr. Allan Gordon for his years of service.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.05 CAD | -9.09% | -9.09% | -28.57% |
05-15 | Resverlogix Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-01 | Resverlogix Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
-28.57% | 11.08M | |
+8.92% | 115B | |
+10.02% | 105B | |
-11.49% | 22.71B | |
+2.21% | 21.83B | |
-10.88% | 18.18B | |
-41.90% | 16.52B | |
-16.16% | 16.01B | |
+2.52% | 14.14B | |
+20.97% | 10.71B |
- Stock Market
- Equities
- RVX Stock
- News Resverlogix Corp.
- Resverlogix Corp. Announces Executive Changes